Introduction {#S1}
============

The adaptive immune system provides protection against disease without inducing harmful autoimmunity; it reacts against the vast and ever-changing array of pathogens that an individual will encounter over a lifetime, while tolerating self. The variable regions of the adaptive immune receptors on B cells and T cells arise through the rearrangement of germline variable, diversity, and joining gene segments ([@B4], [@B5]). Humans each express over 100 million unique immunoglobulins ([@B6]) and a similar number of T-cell receptors ([@B1], [@B7]). The lymphocytes that express these receptors arise, proliferate, and die on time scales of hours to years ([@B1], [@B8]). Thus, the collection of B-cell and T-cell receptor variable region genes expressed at any given time---the adaptive immune receptor repertoire (AIRR)---is dynamic.

Immunoglobulin and T-cell receptor sequences have been studied for decades and several established databases exist including Kabat--Wu and Vbase2 ([@B9], [@B10]). Furthermore, there are databases that incorporate or allow viewing of structural data, such as IMGT, IEDB-3D, AntigenDB, and SAbDab \[reviewed in Ref. ([@B11])\]. These data sets provide important insights into immune receptor--antigen interactions and can inform antibody engineering efforts. However, a single immunoglobulin or T-cell receptor sequence is but a drop of water in the ocean that is the immune repertoire. While many immune repertoire studies have been performed using a variety of methods \[reviewed in Ref. ([@B12])\], adequate analysis of the repertoire as a whole was virtually impossible prior to the advent of high-throughput sequencing (HTS). Here, we focus on HTS-based profiling of AIRR.

Since HTS was first applied to AIRR profiling in 2009 ([@B1], [@B3], [@B6], [@B7]), there has been rapid advancement of both experimental and computational techniques. HTS of AIRRs (AIRR-seq) is yielding valuable insights into how variation in the AIRR differs across lymphocyte subsets ([@B13]--[@B16]) and anatomic compartments ([@B17]--[@B20]), varies over the course of a disease or with therapy ([@B21]--[@B27]), and is influenced by age ([@B28]--[@B32]), genetic background ([@B33], [@B34]), health status ([@B19], [@B29], [@B35]--[@B37]), antigen exposure ([@B27], [@B38]--[@B40]), and other factors. AIRR-seq data are increasingly important in the development of vaccines, monoclonal antibodies, cancer immunotherapies, and other applications \[reviewed in Ref. ([@B41])\]. As the number of datasets continues to grow, comparative analyses of hundreds or even thousands of individuals will soon be feasible. Ensuring the reliability of such integrative analyses, however, will require the establishment of and adherence to standards for reporting and sharing data across multiple laboratories and centers.

Challenges for Airr-Seq Data Sharing {#S2}
====================================

Several challenges currently impede the effective sharing of AIRR-seq data. First, the storage and transport of such large datasets, which can comprise hundreds of millions of sequences (and hundreds of gigabytes) per study, require substantial time and resources. Second, deposition into public archives is not uniformly required by journals or funding agencies. As of September 4, 2017, a Wiki page on the B-T.CR forum[^1^](#fn1){ref-type="fn"} lists 82 AIRR-seq studies that report full HTS data to a public archive,[^2^](#fn2){ref-type="fn"} while 42 (34%) do not.[^3^](#fn3){ref-type="fn"} Third, the information required to ensure appropriate use of such data by secondary users requires delineation ([@B42]). These challenges are not unique to AIRR-seq data. Indeed, the need for shared standards has been recognized and addressed for previous high-throughput technologies ([@B43]), including microarray data ([@B44]).

Another significant challenge for AIRR-seq data is that the processing pipeline between the experiment and the ultimate analysis of the data is lengthy and specialized ([@B45]--[@B59]). Beyond the steps required to process any HTS data, the annotation required of AIRR-seq data is unique to these genes and subject to substantial uncertainty ([@B52]). Unlike other genes, the antigen receptors of adaptive immunity are assembled through the recombination of randomly chosen gene segments, with non-templated nucleotides added to the junctions and nucleotides nibbled away from the gene segments ([@B60]). In B cells, somatic hypermutation during affinity maturation results in further diversification of immunoglobulin genes ([@B61], [@B62]). In order for these data to be effectively shared and reanalyzed, the development of new metadata standards specific to the experimental and bioinformatic methods associated with AIRR-seq are required.

A Brief History of the AIRR Community {#S3}
=====================================

The AIRR Community was established in 2015 at a meeting organized by Felix Breden, Jamie Scott, and Thomas Kepler in Vancouver, BC, USA to address these data sharing challenges. Membership in the AIRR Community is open and is intended to cover all aspects of AIRR-seq technology and its uses. Membership includes researchers expert in the generation of AIRR data; statisticians and bioinformaticians versed in their analysis; informaticians and data security experts experienced in their management; basic scientists and physicians who turn to such data for critical insights; and experts in the ethical, legal, and policy implications of sharing AIRR data.

In 2015, the AIRR Community formed three Working Groups. The Minimal Standards Working Group was tasked with the development of a set of metadata standards for the publication and sharing of AIRR-seq datasets. The Tools and Resources Working Group is focused on the development of standardized resources to facilitate the comparison of AIRR-seq datasets and analysis tools, including collection, validation, and nomenclature of germline alleles. Finally, the Common Repository Working Group is working to establish requirements for repositories that will store AIRR data. The Working Groups are dynamic and often collaborate with each other, as methods evolve and applications of standards in one area (for example, metadata standards) impact other areas (data repository requirements). Full recommendations and membership lists for the Working Groups as well as video recordings of the 2016 AIRR Community meeting are available at <http://www.airr-community.org>. At the June 2016 meeting held at the National Institutes of Health (NIH), the AIRR Community ratified an initial set of recommendations that are summarized herein.

Data Generation {#S4}
===============

Due to the complexity and diversity of the data sets being generated, the AIRR Community is developing best practices for the generation of AIRR-seq data. Such best practice guidelines will include, at a minimum: standard operating procedures for cell isolation and purification, including panels and gating strategies for flow cytometry; primers and protocols for amplification and sequencing of BCR or TCR rearrangements; and a clear description of library preparation and sequencing. Nomenclature is particularly important when it comes to the multiple stages of sample processing and data analysis. For example, what is meant by "raw data" differs among investigators, compounded by the fact that there are multiple levels of data preprocessing.

At present, the AIRR Community recommends that: (1) experimental protocols should be made available through a public repository granting digital object identifiers; (2) the change history of the experimental protocols, including details of what was changed and when the changes were made, should be made publicly available through the same repository; and (3) biological materials (e.g., plasmids, cell lines) should be made available to interested researchers *via* public repositories (e.g., Addgene for vectors, ATCC for cell lines), whenever possible.

Data Sharing {#S5}
============

For transparency and reliable reuse, experiments need to be sufficiently well annotated to allow evaluation of the quality of individual datasets and comparability of different datasets. Therefore, the AIRR Community has developed experimental metadata standards for AIRR-seq data generation, processing, and quality control. The data consist of the raw sequences and the processed sequences, while metadata include clinical and demographic data on study subjects and protocols for cell phenotyping, nucleic acid purification, AIRR amplicon production, HTS library preparation and sequencing, as well as documentation of the computational pipelines used to process the data. In publications or other forms of data sharing, these metadata sets and their components should be described in sufficient detail such that a person skilled in the art of AIRR sequencing and data analysis will be able to reproduce the experiment and data analyses that were performed. A manuscript describing a complete model for AIRR-seq data and metadata, and standardized terminology will soon be submitted.

Data sharing is also premised on the user's ability to locate and access the data. The AIRR Community recommends that all published AIRR-seq data be deposited in designated public repositories that adhere to the AIRR Community minimal standards guidelines, namely, that the data should be made available under the least restrictive terms possible. Limited exceptions to respect commercial interests in intellectual property rights are under consideration by the AIRR Community. To facilitate data sharing, the AIRR Community is also establishing an AIRR Data Commons, comprised of multiple, distributed repositories optimized for storing and querying AIRR-seq data, and supported by a centralized Gateway. Under such an intermediate distributed model ([@B43]), interoperability and effective data sharing are ensured because participating repositories will be required to comply with the community-established data and metadata standards and certain technical requirements.

Legal and Ethical Considerations {#S6}
================================

Adaptive immune receptor repertoire-seq data can be subject to regulations regarding informed consent, intellectual property, and ethical treatment of research subjects. During the process of making AIRR-seq data publicly available, researchers typically would attest that they have sought appropriate informed consent or other authorization for sharing, where applicable. To reduce the potential for a breach of privacy of research subjects, medical and demographic metadata should to be structured in such a way that individual research subjects are not identifiable. Access to health information is regulated by national and international laws, such as the Health Insurance Portability and Accountability Act in the United States or the EU Regulation 2016/679 in the European Union, which requires medical information and personal identifiers to be safeguarded. For studies using AIRR-seq data from human subjects, data must be collected following a protocol that has been approved by the researcher's Institutional Review Board, which oversees human subjects' protections and ensures that all studies are performed in a legal and ethical manner ([@B63]). Human subjects must provide informed consent, and there should be broad agreement in the consent language regarding the confidentiality of medical information and the use of AIRR-seq data and metadata for future research. Without such provisions, the data in the database may be too constrained, with respect to time or breadth of investigation, to be usable by investigators other than the initial data generators.

Whenever data or other items of potential commercial value are shared with others, the individuals who generated and deposited the data should to be given proper credit. Hence, users of the database should, at a minimum, credit the data depositors in any publication or grant application. One mechanism whereby these rules could be followed is to create an online form that must be completed before access to the database is granted. Such a form would essentially be a contract for using the data. Enforcement of the terms of the contract could include monitoring of data use and denying access to the database should the terms of the data-use agreement be violated.

To facilitate broad access to and use of AIRR-seq data, the data should be made available under the least-restrictive terms possible. The default data sharing policy should be to deposit data in a public domain database with no restrictions over deposit, access, storage, curation, or use. For data deposited in public domain databases/repositories, neither the depositors nor the repositories should be permitted to interfere with access to and use of the data by others, including through the assertion of any intellectual property rights. Exceptions to open data sharing may arise in circumstances in which open data sharing would come into conflict with the law, such as those pertaining to personal privacy and protected health information, or into conflict with decisions made by an Institutional Review Board.

Data Analysis {#S7}
=============

The AIRR Community strongly advocates the use of statistical methods for data analysis and hypothesis testing. Statistical methods systematically characterize error, quantify uncertainty, and provide a measure of confidence for inferences. Statistical methods also form the basis for data analysis in all other realms of biomedical and scientific research and should be adopted for AIRR-seq data. Expanded production of AIRR-seq data has been supported by a proliferation of computational tools for their processing and analysis, including tools for variable region gene annotation, inference of clonal history and partitioning and visualization ([@B16], [@B46]--[@B52], [@B55], [@B56], [@B64]--[@B69]). To encourage broad and well-informed use of these tools, the AIRR Community recommends that analysis software be released under an Open Source Initiative approved license, hosted on a publicly available website or repository with versioning, and be designed for modularity and inter-operability with other software. The AIRR Community will promote best practices in AIRR-seq data analysis by: (1) developing and publishing common criteria for the evaluation of statistical methods; (2) providing common "gold-standard" datasets of multiple types for use in software development, testing, and calibration; and (3) establishing best practices for data sharing and analysis software platforms.

Conclusion {#S8}
==========

Members of the AIRR Community have worked together for over 2 years with enthusiasm, driven by the belief that optimizing the reproducibility and sharing of AIRR-seq data will have a profound and positive effect on biomedical research and patient care. To encourage widespread adoption, the AIRR Community recommends that journals and funding agencies require AIRR-seq data be made available through a public data repository after publication or as negotiated in data-sharing agreements for unpublished data. The success of this initiative is also critically dependent upon acceptance by the researchers who generate and use AIRR-seq data. While members of the AIRR Community have tried to be inclusive through developing contacts with researchers in the field and extensively advertising the annual meetings, there are likely to be many researchers who generate, analyze, and use AIRR-seq data, who are not aware of the AIRR Community initiative. Community "buy in" results from creating data standards that are transparently developed through public discussion, robustly evaluated, and periodically updated as the field advances. This Perspective represents an open invitation to the larger scientific community to participate in and adopt the AIRR initiative. To that end, we welcome feedback on this Perspective and on the AIRR Community's efforts to date. Individuals interested in working on any facet of this important initiative are invited to attend, in person or online, the 2017 Community Meeting hosted by the NIH in Rockville, MD, USA, December 3--6, 2017. Most of all, we encourage anyone who is interested to join the AIRR Community[^4^](#fn4){ref-type="fn"} and participate in the working groups.
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